NEW ORLEANS & RALEIGH, N.C.--(BUSINESS WIRE)--Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced the presentation of data from its Phase 3 pivotal clinical trials evaluating the efficacy and tolerability of XIFAXAN 550 mg (rifaximin) – its minimally-absorbed, gut-selective, broad-spectrum antibiotic – in 1,260 patients with non-constipation irritable bowel syndrome (IBS) during the Distinguished Abstract Plenary Presentation at the annual meeting of Digestive Disease Week (DDW) being held this week in New Orleans (May 1-5, 2010). These data demonstrated that a 14-day course of XIFAXAN 550 mg, taken 3 times daily, achieved adequate relief of IBS symptoms in a significantly greater proportion of patients during the first 4 weeks following 2 weeks of treatment, as well as over 3 months (2-week treatment plus 10-week follow-up), compared with placebo. The safety profiles were similar between XIFAXAN 550 mg and placebo.
